参考文献/References:
[1] National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification [J].Am J Kidney Dis,2002,39(2,Supplement 1):S1-S266.
[2] Zhang L,Wang F,Wang L,et al. Prevalence of chronic kidney disease in China:a cross-sectional survey[J].The Lancet,2012,379(9818):815-822.
[3] Go AS,Chertow GM,Fan D,et al. Chronic kidney disease and the risks of death,cardiovascular events,and hospitalization[J]. N Engl J Med,2004,351(13):1296-1305.
[4] Fox CS,Muntner P,Chen AY,et al. Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease:a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry[J]. Circulation,2010,121(3):357-365.
[5] Jagiela J,Bartnicki P,Rysz J. Selected cardiovascular risk factors in early stages of chronic kidney disease[J]. Int Urol Nephrol,2020,52(2):303-314.
[6] Nakano T,Katsuki S,Chen M,et al. Uremic toxin indoxyl sulfate promotes proinflammatory macrophage activation via the interplay of OATP2B1 and Dll4-Notch signaling[J]. Circulation,2019,139(1):78-96.
[7] Ferro C J,Mark P B,Kanbay M,et al. Lipid management in patients with chronic kidney disease[J]. Nat Rev Nephrol,2018,14(12):727-749.
[8] 李国斌，蒋颍，刘冰洁，等. 冠心病合并慢性肾脏病患者的抗栓治疗进展[J]. 心血管病学进展,2019,40(1):117-120.
[9] Catapano AL,Graham I,de Backer G,et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias[J]. Eur Heart J,2016,37(39):2999-3058.
[10] Tonelli M,Isles C,Curhan GC,et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease[J]. Circulation,2004,110(12):1557-1563.
[11] Ridker PM,Macfadyen JG,Nordestgaard BG,et al. Rosuvastatin for primary prevention among individuals with elevated high-sensitivity C-reactive protein and 5% to 10% and 10% to 20% 10-year risk. Implications of the Justification for Use of Statins in Prevention:an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial for "intermediate risk"[J]. Circ Cardiovasc Qual Outcomes,2010,3(5):447-452.
[12] Shepherd J,Kastelein JJ,Bittner V,et al. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease:the TNT (Treating to New Targets) study[J]. J Am Coll Cardiol,2008,51(15):1448-1454.
[13] Launay-Vacher V,Izzedine H,Deray G. Statins’dosage in patients with renal failure and cyclosporine drug-drug interactions in transplant recipient patients[J]. Int J Cardiol,2005,101(1):9-17.
[14] Wanner C,Tonelli M. KDIGO Clinical Practice Guideline for Lipid Management in CKD:summary of recommendation statements and clinical approach to the patient[J]. Kidney Int,2014,85(6):1303-1309.
[15] Wanner C,Krane V,Marz W,et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis[J]. N Engl J Med,2005,353(3):238-248.
[16] Baigent C,Landray MJ,Reith C,et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection):a randomised placebo-controlled trial[J]. Lancet,2011,377(9784):2181-2192.
[17] Katsiki N,Mikhailidis DP,Banach M. Lipid-lowering agents for concurrent cardiovascular and chronic kidney disease cardiovascular and chronic kidney disease[J]. Expert Opin Pharmaco,2019,20(16):1017-2007.
[18] Sandhu S,Wiebe N,Fried LF,et al. Statins for improving renal outcomes:a meta-analysis[J]. J Am Soc Nephrol,2006,17(7):2006-2016.
[19] Fried LF. Effects of HMG-CoA reductase inhibitors (statins) on progression of kidney disease[J]. Kidney Int,2008,74(5):571-576.
[20] Katsiki N,Athyros VG,Karagiannis A,et al. Ezetimibe and low density lipoprotein subfractions:an ongoing debate[J]. Curr Med Res Opin,2011,27(3):693-695.
[21] Cannon CP,Blazing MA,Giugliano RP,et al. Ezetimibe added to statin therapy after acute coronary syndromes[J]. N Engl J Med,2015,372(25):2387-2397.
[22] Stanifer JW,Charytan DM,White J,et al. Benefit of ezetimibe added to simvastatin in reduced kidney function[J]. J Am Soc Nephrol,2017,28(10):3034-3043.
[23] Katsiki N,Theocharidou E,Karagiannis A,et al. Ezetimibe therapy for dyslipidemia:an update[J]. Curr Pharm Des,2013,19(17):3107-3114.
[24] Morita T,Morimoto S,Nakano C,et al. Renal and vascular protective effects of ezetimibe in chronic kidney disease[J]. Intern Med,2014,53(4):307-314.
[25] Keech A,Simes RJ,Barter P,et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study):randomised controlled trial[J]. Lancet,2005,366(9500):1849-1861.
[26] Tsimihodimos V,Mikhailidis DP,Elisaf M. Summarizing the FIELD study:lessons from a ’negative’ trial[J]. Expert Opin Pharmacother,2013,14(18):2601-2610.
[27] Agouridis AP,Nair DR,Mikhailidis DP. Strategies to overcome statin intolerance[J]. Expert Opin Drug Metab Toxicol,2015,11(6):851-855.
[28] Jun M,Zhu B,Tonelli M,et al. Effects of fibrates in kidney disease:a systematic review and meta-analysis[J]. J Am Coll Cardiol,2012,60(20):2061-2071.
[29] Sica DA. Fibrate therapy and renal function[J]. Curr Atheroscler Rep,2009,11(5):338-342.
[30] Kostapanos MS,Florentin M,Elisaf MS. Fenofibrate and the kidney:an overview[J]. Eur J Clin Invest,2013,43(5):522-531.
[31] Davidson MH,Armani A,McKenney JM,et al. Safety vonsiderations with fibrate therapy[J]. Am J Cardiol,2007,99(6A):3C-18C.
[32] Landray MJ,Haynes R,Hopewell JC,et al. Effects of extended-release niacin with laropiprant in high-risk patients[J]. N Engl J Med,2014,371(3):203-212.
[33] Boden WE,Probstfield JL,Anderson T,et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy[J]. N Engl J Med,2011,365(24):2255-2267.
[34] Streja E,Kovesdy CP,Streja DA,et al. Niacin and progression of CKD[J]. Am J Kidney Dis,2015,65(5):785-798.
[35] Silverman MG,Ference BA,Im K,et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions:a systematic review and meta-analysis[J]. JAMA,2016,316(12):1289-1297.
[36] Zheng-Lin B,Ortiz A. Lipid management in chronic kidney disease:systematic review of PCSK9 targeting[J]. Drugs,2018,78(2):215-229.
[37] Chaudhary R,Garg J,Shah N,et al. PCSK9 inhibitors:a new era of lipid lowering therapy[J]. World J Cardiol,2017,9(2):76-91.
[38] Sabatine MS,Giugliano RP,Keech AC,et al. Evolocumab and clinical outcomes in patients with cardiovascular disease[J]. N Engl J Med,2017,376(18):1713-1722.
[39] Schwartz GG,Steg PG,Szarek M,et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome[J]. N Engl J Med,2018,379(22):2097-2107.
[40] Toth PP,Dwyer JP,Cannon CP,et al. Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease[J]. Kidney Int,2018,93(6):1397-1408.
[41] Xu T,Sun Y,Sun W,et al. Effect of omega-3 fatty acid supplementation on serum lipids and vascular inflammation in patients with end-stage renal disease:a meta-analysis[J]. Sci Rep,2016,6:39346.
[42] Bhatt DL,Steg PG,Miller M,et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia[J]. N Engl J Med,2019,380(1):11-22.
[43] Perez-Martinez P,Katsiki N,Mikhailidis DP. The role of n-3 fatty acids in cardiovascular disease:back to the future[J]. Angiology,2020,71(1):10-16.
[44] Saglimbene VM,Wong G,van Zwieten A,et al. Effects of omega-3 polyunsaturated fatty acid intake in patients with chronic kidney disease:Systematic review and meta-analysis of randomized controlled trials[J]. Clin Nutr,2020,39(2):358-368.
[45] Han E,Yun Y,Kim G,et al. Effects of omega-3 fatty acid supplementation on diabetic nephropathy progression in patients with diabetes and hypertriglyceridemia[J].PloS One,2016,11(5):e154683.
相似文献/References:
[1]周小琳 何泉.替格瑞洛在急性冠脉综合征合并慢性肾脏病患者中的应用研究进展[J].心血管病学进展,2019,(5):718.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.014]
ZHOU Xiaolin,HE Quan.Ticagrelor in Acute Coronary Syndrome with Chronic Kidney Disease[J].Advances in Cardiovascular Diseases,2019,(10):718.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.014]
[2]史云聪 郭艺芳.2型糖尿病和动脉粥样硬化性心血管疾病的关系[J].心血管病学进展,2020,(5):485.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.011]
SHI Yuncong,GUO Yifang.Relationship Between Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(10):485.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.011]
[3]李艳茹,白世茹,李如意,等.PCSK9抑制剂在血脂代谢中的研究进展[J].心血管病学进展,2020,(7):729.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.014]
LI Yanru,BAI Shiru,LI Ruyi,et al.PCSK9 Inhibitors in Lipid Metabolism[J].Advances in Cardiovascular Diseases,2020,(10):729.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.014]
[4]马晓磊 朱国斌.Wnt信号与动脉粥样硬化性心血管疾病研究进展[J].心血管病学进展,2020,(8):855.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.018]
MA Xiaolei,ZHU Guobin.Wnt Signaling and Atherosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(10):855.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.018]
[5]姚雅洁 蔡恒.PCSK9抑制剂Evolocumab动脉粥样硬化性心血管疾病的研究进展[J].心血管病学进展,2020,(12):1285.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.015]
YAO Yajie,CAI Heng.PCSK9 Inhibitor Evolocumab and ASCVD[J].Advances in Cardiovascular Diseases,2020,(10):1285.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.015]
[6]曹岩 颜培实.残余胆固醇与动脉粥样硬化性心血管疾病[J].心血管病学进展,2021,(10):920.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.014]
CAO Yan,YAN Peishi.Remnant Cholesterol And Atherosclerotic?ardiovascular Disease[J].Advances in Cardiovascular Diseases,2021,(10):920.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.014]
[7]蔡薇 杨堰焯 刘昊凌.甘油三酯葡萄糖乘积指数与糖尿病血管病变的研究进展[J].心血管病学进展,2022,(3):245.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]
CAI Wei,YANG Yanzhuo,LIU Haoling.Triglyceride-Glucose Index and Diabetic Vascular Disease[J].Advances in Cardiovascular Diseases,2022,(10):245.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]
[8]陈林滔 田清平 刘梅林.残余胆固醇预测动脉粥样硬化性心血管疾病的研究进展[J].心血管病学进展,2022,(6):492.[doi:10.16806/j.cnki.issn.1004-3934.2022.06.004]
CHEN Lintao,TIAN Qingping,LIU Meilin.Remnant Cholesterol in Predicting Atherosclerotic Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2022,(10):492.[doi:10.16806/j.cnki.issn.1004-3934.2022.06.004]
[9]陈纪元 陆泓雨 贺子熠 韩江莉.冠心病合并慢性肾脏病患者P2Y12受体拮抗剂治疗进展[J].心血管病学进展,2022,(7):582.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
CHEN Jiyuan,LU Hongyu,HE Ziyi,et al.P2Y12 Antagonists for Patients with Chronic Kidney Diseases and Coronary Heart Diseases[J].Advances in Cardiovascular Diseases,2022,(10):582.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
[10].胆固醇酯转移蛋白抑制剂在动脉粥样硬化性心血管疾病治疗中的研究进展[J].心血管病学进展,2022,(7):600.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
ZHU Jie,GAO Fen,XUE Shuanqin,et al.Treatment of Atherosclerotic Cardiovascular Diseases with Cholesteryl Ester Transfer Protein Inhibitor[J].Advances in Cardiovascular Diseases,2022,(10):600.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]